{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:52:37Z","timestamp":1784119957759,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Total neoadjuvant therapy (TNT) has emerged as a therapeutic approach for locally advanced rectal cancer (LARC). However, the optimal chemotherapy cycles within TNT remain uncertain. This study aimed to evaluate and compare the prognostic efficacy of varying cycles of chemotherapy during TNT for LARC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients diagnosed with LARC (T3-4N0M0\/T1-4N1-2M0), who underwent TNT or chemoradiotherapy followed by total mesorectal excision (TME) between 2015 and 2020, were retrospective included. Patients were categorized into three groups based on their neoadjuvant strategy: CRT (long-course chemoradiotherapy), STNT (long-course CRT with one to three cycles of chemotherapy), and LTNT (long-course CRT with four or more cycles of chemotherapy). Propensity score matching (PSM) based on gender, age, body mass index, tumor distance from the anal verge, clinical T stage, clinical N stage, and mesorectal fascia status was employed to reduce confounding bias. Primary endpoints were disease-free survival (DFS) and metastasis-free survival (MFS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study comprised 372 patients, with 73 patients in each group after PSM. Compared with CRT, both STNT and LTNT demonstrated improved DFS (5-year rate: 59.7% vs. 77.8% vs. 76.5%, p\u2009=\u20090.027) and MFS (5-year rate: 65.1% vs. 81.3% vs. 81.4%, p\u2009=\u20090.030). There was no difference in DFS or MFS between STNT and LTNT. These favorable outcomes were consistent among subgroups defined by tumor distance from the anal verge\u2009\u2265\u20095\u00a0cm, clinical T3 stage, clinical N positive status, or involved mesorectal fascia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Compared to CRT, both STNT and LTNT demonstrated improved DFS and MFS outcomes. Notably, survival outcomes were similar between STNT and LTNT, suggesting that chemotherapy cycles in TNT may not significantly impact survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00384-024-04610-1","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T06:02:11Z","timestamp":1710568931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Total neoadjuvant therapy for locally advanced rectal cancer: a three-group propensity score matched study"],"prefix":"10.1007","volume":"39","author":[{"given":"Jiahao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zikai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8149-5989","authenticated-orcid":false,"given":"Qingbin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"key":"4610_CR1","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1200\/JCO.2007.15.3858","volume":"26","author":"M Braendengen","year":"2008","unstructured":"Braendengen M, Tveit KM, Berglund A et al (2008) Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 26:3687\u20133694","journal-title":"J Clin Oncol"},{"key":"4610_CR2","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731\u20131740","journal-title":"N Engl J Med"},{"key":"4610_CR3","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","volume":"30","author":"R Sauer","year":"2012","unstructured":"Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30:1926\u20131933","journal-title":"J Clin Oncol"},{"key":"4610_CR4","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/annonc\/mdu560","volume":"26","author":"AJ Breugom","year":"2015","unstructured":"Breugom AJ, van Gijn W, Muller EW et al (2015) Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 26:696\u2013701","journal-title":"Ann Oncol"},{"key":"4610_CR5","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1200\/JCO.19.00016","volume":"37","author":"YS Hong","year":"2019","unstructured":"Hong YS, Kim SY, Lee JS et al (2019) Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial. J Clin Oncol 37:3111\u20133123","journal-title":"J Clin Oncol"},{"key":"4610_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22:702\u2013715","journal-title":"Lancet Oncol"},{"key":"4610_CR7","doi-asserted-by":"publisher","first-page":"e180071","DOI":"10.1001\/jamaoncol.2018.0071","volume":"4","author":"A Cercek","year":"2018","unstructured":"Cercek A, Roxburgh CSD, Strombom P et al (2018) Adoption of total neoadjuvant therapy for locally advanced rectal Cancer. JAMA Oncol 4:e180071","journal-title":"JAMA Oncol"},{"key":"4610_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/oncolo\/oyac025","volume":"27","author":"JK Kim","year":"2022","unstructured":"Kim JK, Marco MR, Roxburgh CSD et al (2022) Survival after induction chemotherapy and chemoradiation versus chemoradiation and adjuvant chemotherapy for locally advanced rectal cancer. Oncologist 27:380\u2013388","journal-title":"Oncologist"},{"key":"4610_CR9","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/bjs\/znad120","volume":"110","author":"Q Wu","year":"2023","unstructured":"Wu Q, Zhou J, Huang J et al (2023) Total neoadjuvant therapy versus chemoradiotherapy for locally advanced rectal cancer: bayesian network meta-analysis. Br J Surg 110:784\u2013796","journal-title":"Br J Surg"},{"key":"4610_CR10","doi-asserted-by":"publisher","first-page":"770767","DOI":"10.3389\/fsurg.2021.770767","volume":"8","author":"Y Fang","year":"2021","unstructured":"Fang Y, Sheng C, Ding F et al (2021) Adding consolidation capecitabine to neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a propensity-matched comparative study. Front Surg 8:770767","journal-title":"Front Surg"},{"key":"4610_CR11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(15)00004-2","volume":"16","author":"J Garcia-Aguilar","year":"2015","unstructured":"Garcia-Aguilar J, Chow OS, Smith DD et al (2015) Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 16:957\u2013966","journal-title":"Lancet Oncol"},{"key":"4610_CR12","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1097\/DCR.0000000000001207","volume":"61","author":"MR Marco","year":"2018","unstructured":"Marco MR, Zhou L, Patil S et al (2018) Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial. Dis Colon Rectum 61:1146\u20131155","journal-title":"Dis Colon Rectum"},{"key":"4610_CR13","unstructured":"National Comprehensive Cancer Network (2022) NCCN guidelines: rectal cancer. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/rectal.pdf. Accessed 4 Aug"},{"key":"4610_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.radonc.2020.03.039","volume":"148","author":"CAM Marijnen","year":"2020","unstructured":"Marijnen CAM, Peters FP, Rodel C et al (2020) International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiother Oncol 148:213\u2013215","journal-title":"Radiother Oncol"},{"issue":"Suppl 4","key":"4610_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/annonc\/mdp128","volume":"20","author":"B Glimelius","year":"2009","unstructured":"Glimelius B, Oliveira J (2009) Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):54\u201356","journal-title":"Ann Oncol"},{"key":"4610_CR16","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/archsurg.133.8.894","volume":"133","author":"RJ Heald","year":"1998","unstructured":"Heald RJ, Moran BJ, Ryall RD et al (1998) Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978\u20131997. Arch Surg 133:894\u2013899","journal-title":"Arch Surg"},{"key":"4610_CR17","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/DCR.0000000000001965","volume":"65","author":"Q Wu","year":"2022","unstructured":"Wu Q, Jin Z, Zhang X et al (2022) Effect of tumor location on outcome after laparoscopic low rectal cancer surgery: a propensity score matching analysis. Dis Colon Rectum 65:672\u2013682","journal-title":"Dis Colon Rectum"},{"key":"4610_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/biomet\/87.3.706","volume":"87","author":"G Imbens","year":"2000","unstructured":"Imbens G (2000) The role of the propensity score in estimating dose-response functions. Biometrika 87:706\u2013710","journal-title":"Biometrika"},{"key":"4610_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/EDE.0b013e318289dedf","volume":"24","author":"JA Rassen","year":"2013","unstructured":"Rassen JA, Shelat AA, Franklin JM et al (2013) Matching by propensity score in cohort studies with three treatment groups. Epidemiology 24:401\u2013409","journal-title":"Epidemiology"},{"key":"4610_CR20","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/annonc\/mdv223","volume":"26","author":"C Fernandez-Martos","year":"2015","unstructured":"Fernandez-Martos C, Garcia-Albeniz X, Pericay C et al (2015) Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol 26:1722\u20131728","journal-title":"Ann Oncol"},{"key":"4610_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.clcc.2021.01.001","volume":"20","author":"S Yu","year":"2021","unstructured":"Yu S, Mamtani R, O\u2019Hara MH et al (2021) Comparative effectiveness of total neoadjuvant therapy versus standard adjuvant chemotherapy for locally advanced rectal cancer. Clin Colorectal Cancer 20:121\u2013129","journal-title":"Clin Colorectal Cancer"},{"key":"4610_CR22","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s00384-022-04179-7","volume":"37","author":"H Zhang","year":"2022","unstructured":"Zhang H, Li G, Cao K et al (2022) Impact of total neoadjuvant therapy consisting of consolidation chemotherapy on locally advanced rectal cancer survival. Int J Colorectal Dis 37:1657\u20131668","journal-title":"Int J Colorectal Dis"},{"key":"4610_CR23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ijrobp.2018.04.013","volume":"101","author":"SY Kim","year":"2018","unstructured":"Kim SY, Joo J, Kim TW et al (2018) A randomized phase 2 trial of consolidation chemotherapy after preoperative chemoradiation therapy versus chemoradiation therapy alone for locally advanced rectal Cancer: KCSG CO 14\u2009\u2013\u200903. Int J Radiat Oncol Biol Phys 101:889\u2013899","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4610_CR24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00428-021-03108-3","volume":"479","author":"G Chotard","year":"2021","unstructured":"Chotard G, Capdepont M, Denost Q et al (2021) Effects of neoadjuvant chemotherapy plus chemoradiotherapy on lymph nodes in rectal adenocarcinoma. Virchows Arch 479:657\u2013666","journal-title":"Virchows Arch"},{"key":"4610_CR25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1200\/JCO.23.01208","volume":"42","author":"FS Verheij","year":"2024","unstructured":"Verheij FS, Omer DM, Williams H et al (2024) Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA Trial. J Clin Oncol 42:500\u2013506","journal-title":"J Clin Oncol"},{"key":"4610_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22:29\u201342","journal-title":"Lancet Oncol"},{"key":"4610_CR27","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","volume":"278","author":"EA Dijkstra","year":"2023","unstructured":"Dijkstra EA, Nilsson PJ, Hospers GAP et al (2023) Locoregional failure during and after short-course Radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg 278:e766\u2013e772","journal-title":"Ann Surg"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-024-04610-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-024-04610-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-024-04610-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T09:17:50Z","timestamp":1736327870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-024-04610-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4610"],"URL":"https:\/\/doi.org\/10.1007\/s00384-024-04610-1","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]},"assertion":[{"value":"4 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was authorized by the ethics committee of west China hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}